clinical trial · NCT02771795
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
Samsung Bioepis Co., Ltd.·—·terminated·n = 538
Breast NeoplasmsHerceptin (trastuzumab)SB3 (proposed trastuzumab biosimilar)
brief summary
A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
started
Apr 1, 2016
primary completion
Dec 1, 2020
completion
Dec 1, 2020
last updated
Feb 2, 2024
official title
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol